AOM International Group Company Limited Overview
AOM International is a Hong Kong-listed, Bermuda-domiciled investment holding company with a portfolio of small consumer and agricultural businesses that have little in common with each other. About two-thirds of revenue comes from an OEM/licensed toys and gifts business that sells mainly to a few North American customers. The rest comes from a 51%-owned Hubei-based traditional Chinese medicine (TCM) herb and decoction-piece maker (Hubei Jincaotang) and a 60%-owned Fujian wine trading platform built around the heritage "Gushan" (鼓山) huangjiu (yellow rice wine) brand. Beneath these operating units sit loss-making associates: Jiangxi forestry land, a Samoa resort/casino development, Anhui yellow wine and Fujian tea. These associates have generated repeated share-of-loss and impairment charges. The group is loss-making (FY2025 attributable loss HK$121.7M), has net current liabilities, has defaulted on secured borrowings, and its auditor has flagged a going-concern material uncertainty. Its strategy since 2024 has been serial diversification into liquor, health food, medicinal-stew restaurants and digital-economy platforms, funded by repeated equity issuance.
Company's own description
The FY2025 results announcement describes the Company's principal activity as investment holding. It says the Group is principally engaged in four areas: (i) manufacturing and trading of toys and gifts items; (ii) development, processing and manufacturing of Chinese herbs products; (iii) investment in various businesses including fruit plantation, leisure and culture; and (iv) trading of wines, food and beverage products. Item (iv) was added in FY2024 after the Fujian Laojiu acquisition and widened in FY2025 to cover food and beverage.
Independent characterisation
In practice, AOM is a holding company with three revenue-generating businesses. Several equity-accounted associates and legacy investments sit alongside them; these produce no revenue and consume capital.
-
Toys & gifts (65% of FY2025 revenue). This is a manufacturing and trading business whose largest customers are in North America. North America provided 63.2% of group revenue in FY2025. Cost of sales includes licence fees (HK$7.7M in FY2025) and royalty fees (HK$15.3M), so a meaningful part of the range is licensed product. The business depends heavily on a few customers: Customer A alone bought HK$79.6M (26.5% of group revenue) in FY2025. The US subsidiary reports in USD.
-
Chinese herbs (18%). Hubei Jincaotang Pharmaceutical Co., Ltd. (湖北金草堂藥業有限公司), 51%-owned since 2021, makes TCM herbs and decoction pieces (飲片) in Mainland China. It is backward-integrating into its own herb plantation bases.
-
Wines, food & beverage (17%). Fujian Laojiu Investment Co., Ltd., 60%-owned since 31 May 2024, trades wine (huangjiu) in Mainland China. In FY2025 this was briefly supplemented by commission income from food and beverage trading through Heilongjiang Yingli, which was acquired in Oct 2025 and sold in H1 2026.
Revenue model mix (FY2025)
| Revenue model | FY2025 HKD Mn | % of total |
|---|---|---|
| Manufacturing — toys and gifts | 122.6 | 40.8 |
| Manufacturing — Chinese herbs products | 54.4 | 18.1 |
| Trading — toys and gifts | 72.9 | 24.2 |
| Trading — wines, food and beverage (incl. HK$3.3M commission) | 50.8 | 16.9 |
| Total | 300.6 | 100.0 |
All revenue is product revenue recognised at a point in time. There is no subscription, licensing-out or service revenue.
Value-chain position, customers and end-markets
| Business | Value-chain position | Customer type | End-market |
|---|---|---|---|
| Toys & gifts | Contract/licensed manufacturer plus trading intermediary | Large North American retailers/brand owners (concentrated); small UK sales began FY2025 | US/Canada consumer toys and gifts |
| Chinese herbs | Upstream cultivation, processing and decoction-piece manufacturing | Hospitals, pharmacies, TCM distributors in PRC (inferred from the decoction business; customer types not itemised) | PRC TCM pharmaceuticals |
| Wines/F&B | Brand-owner/distributor of Fujian huangjiu; trading | Distributors, retail channels; 2026 plan for stew-pot restaurants | PRC alcoholic beverages / catering |
| Associates | Passive minority holdings | — | PRC forestry/eco-tourism, Samoa resort, PRC tea, Anhui huangjiu |
Strategy
Stated strategy (themes from filings)
Diversified investment strategy: Management repeatedly describes "exploring other investment opportunities that have earning potentials… to diversify its businesses and income base." The FY2025 MD&A explicitly ties the 2024 entry into wine trading to this strategy.
Vertical integration in TCM: Own herb plantation bases are presented as a 10-year plan for quality, cost control and supply security, aligned with PRC policy on optimising the TCM industry.
Liquor and health-food consumption: Positioning in huangjiu, health catering (stew pots, medicinal cuisine), premium cultural wine and cooking wine.
Digital economy and cross-border capital services (2026): Described by the board as consistent with "strengthening the core business and increasing shareholder value" and with diversifying risk.
Initiative register (last 24 months)
| Date | Initiative | Detail | Financial commitment |
|---|---|---|---|
| 31 May 2024 | Wine trading entry | Fujian Laojiu Investment 60% | — |
| 24 Oct 2024 | Beijing wine HQ | Office purchase RMB51.6M | Cancelled Jun 2025; deposit refunded |
| Nov–Dec 2024 | Rebrand to AOM International | Name/stock short name change | — |
| Jan 2025 | Sales-network expansion with IT firm | Subsidiary cooperation with an IT company (per news feed) | — |
| 16 Jan 2025 | Medicinal-stew stores | Agreement with Hunan Shilin Commercial Management | — |
| 22 Oct 2025 | F&B trading | Heilongjiang Yingli 65% for RMB6.5M | Reversed H1 2026 (sold for RMB3.0M) |
| 17 Apr 2026 | Fujian Laojiu stew-pot stores | Self-operated plus franchise launch in 2026 | — |
| 26 Jun 2026 | Cooking-wine distribution | Fujian Laojiu Sales 51% for HK$100M CB | HK$100M CB at HK$0.16 |
| 27 Jul 2026 | Digital economy platform | Hainan Lianshang JV via Yuanmingtang (Guangzhou); 3-year agreement; Boao Global Digital Economy Conference co-host; "Samoa cross-border listing" services | Capital injection amount not disclosed in media summary |
| 6 Oct 2026 | Twelve Dynasties Wine | Premium aged huangjiu / cultural export | — |
| Ongoing | TCM plantation bases | Prepaid plantation contracts; HK$13.6M herbs capex FY2025 | HK$13.6M (FY2025 additions) |
| Ongoing | Balance-sheet repair | Rights issue / open offer / placing / CB under consideration; lender negotiations | Not quantified |
ESG commitments, cost programmes and targets
ESG commitments: ESG reports for 2022, 2024 and 2025 were posted on 29 Jun 2026. No quantified targets were identified.
Cost programmes: None announced.
Medium-term targets/guidance: None publicly disclosed.
Products & Services
The company discloses very little product-level detail. The catalog below lists only what filings and announcements name; anything not named is marked as not disclosed.
Toys and gifts
| Offering | Description | Target customer | Launch/version | Pricing model | Named flagship |
|---|---|---|---|---|---|
| Manufactured toys and gifts | In-house/subcontracted manufacturing (HK$122.6M revenue FY2025). Licence fees (HK$7.7M) and royalties (HK$15.3M) indicate licensed IP products | North American retailers/brand owners; UK from FY2025 | — | B2B unit pricing; 90-day credit terms (FY2023 disclosure) | — |
| Traded toys and gifts | Sourced-and-resold product (HK$72.9M FY2025) | Same | — | B2B | — |
Chinese herbs (Hubei Jincaotang)
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| TCM herb products / decoction pieces (飲片) | Development, processing and manufacturing of Chinese herbs and the decoction business in Mainland China | PRC healthcare channel (not itemised) | 120-day credit terms (FY2023) |
| Herb plantation bases | Infrastructure (including roads) built in 2023; 3–5-year contracts with local farming organisations (prepaid plantation costs HK$9.8M at end-2025); biological assets HK$5.8M | Internal supply | Management cites quality control, cost and supply security |
Wines, food and beverage
| Offering | Description | Status |
|---|---|---|
| Fujian Laojiu wine trading | Wine trading in Mainland China (HK$47.5M wine sales FY2025) | Operating |
| "Gushan" (鼓山) huangjiu brand | A Fujian rice-wine heritage claimed to date back about 200 years (Daxing winery, Daoguang era); trademark registered 1958 (per Apr 2026 announcement) | Brand linked to the Fujian Laojiu group |
| Fujian Laojiu stew-pot (燉罐) restaurants | Self-operated plus franchise health-cuisine stores using Gushan wine; positioned for health-oriented catering | Announced 17 Apr 2026 for launch in 2026 |
| Medicinal-stew stores (Hunan Shilin cooperation) | Development of medicinal cuisine stew stores | Agreement 16 Jan 2025; results not disclosed |
| "Twelve Dynasties Wine" (十二朝代酒) | Premium aged huangjiu in handmade Jingdezhen porcelain bottles with artwork by landscape painter Chen Chunyong; marketed as a cultural export product | Announced 6 Oct 2026 |
| F&B commission trading (Heilongjiang Yingli) | Commission income HK$3.3M (FY2025) | Disposed in H1 2026 for RMB3.0M (gain about HK$2.4M) |
| Cooking-wine distribution (Fujian Laojiu Sales, 51%) | Cooking-wine (料酒) distributor; intended to integrate sales network and gain pricing control | Pending major transaction (Jun 2026) |
Non-revenue holdings
| Holding | Description |
|---|---|
| Multijoy Group (40%) | Forestry concession, Nanfeng County, Jiangxi (1,765.53 mu); converting to an ecological sightseeing farm |
| USO Management & Holding (Samoa) | Joint development of leased land for residential, luxury hotel/casino and villas; construction start delayed to Oct 2026 (previously Jan 2025) |
| Fujian Yuguo (tea) | Tea associate; share of loss about HK$15K in FY2025 |
| Anhui Fu Lao (20%) | Huangjiu producer; ownership enforcement litigation ongoing |
| Outbound tourism | No turnover since at least FY2022 |
| Inner Mongolia coal exploration | Fully written down |
| Culture (ceramics) | Dormant |
Financial Narrative
Sources: FY2025 and FY2024 come from the FY2025 Annual Results Announcement. FY2023 and FY2022 come from the FY2023 Annual Results Announcement.
Income statement: notes and sources
Notes: FY2021 cost of sales is derived (revenue minus GP). FY2021 operating income, EBITDA and D&A are aggregator values; the aggregator's FY2021 EBITDA (-57.6) is not reconcilable with its operating income and D&A, so treat FY2021 as indicative only. Zeros in FY2021 rows mean "not available," not literal zero. Aggregator operating income for FY2022–FY2025 differs from the derived figures above because of different classification. One data feed (Express News) reported FY2024 attributable net income as HKD -17.2M, but the audited figure is HK$-84.6M. Another (Moomoo/Zhitong) rendered FY2023 attributable profit as "HK$372.13 million"; the audited figure is HK$37.2M. The filed figures above prevail.
Key FY2023 and FY2025 non-operating items
FY2023's reported profit was not an operating profit. A HK$92.0M gain from writing off time-barred promissory notes and a HK$28.4M gain on loan capitalisation more than explain the HK$69.1M pre-tax profit. Excluding them, FY2023 would have shown a pre-tax loss of about HK$51M.
Per-share data
The weighted share count rose more than eightfold from FY2022 to FY2025 even after three consolidations (5:1 in Jun 2022, 5:1 in Apr 2023, 2:1 in Jan 2024). This reflects heavy dilution from placings, CB conversions and loan capitalisations.
Margins (%; derived)
Revenue CAGR: FY2021 to FY2025 is -1.8% a year. FY2020 to FY2025 is about +8.1% a year, using aggregator FY2020 revenue of HK$203.4M; most of that growth came from the Hubei Jincaotang acquisition in 2021. FY2022 to FY2025 is -10.6% a year.
Balance sheet
The company's gearing ratio uses a broad net-debt definition that includes trade payables, accruals and other payables, divided by total equity. At 30 Jun 2026 (interim, per media), cash was about HK$110.0M, borrowings about HK$235.4M, gearing 67.9% and net current liabilities about HK$7.6M.
Default disclosure (FY2025): Secured other borrowings of HK$63.9M plus accrued interest of HK$37.9M were in default. About HK$37.5M owed to a shareholder became subject to a written undertaking not to demand repayment before 31 Mar 2027.
Cash flow
The full consolidated cash-flow statements were not contained in the results announcements reviewed. Operating cash flow, capex and free cash flow are therefore not publicly disclosed in the sources reviewed; refer to the full annual reports. Available proxies:
The rise in cash in FY2024 and FY2025 should not be read as operating cash generation. FY2024 benefited from the HK$51.3M placing. FY2025 benefited from the refund of the RMB45M (about HK$49.0M) Beijing property deposit, while borrowings rose by about HK$60M.
Ratios (derived)
ROIC row: not computed (zeros = not meaningful) because NOPAT is negative or distorted in most years and tax and invested-capital definitions are unclear.
Commentary on trends and inflections
Revenue. Revenue peaked in FY2022 at HK$420.9M, the first full-year consolidation of Hubei Jincaotang. It has since fallen 28.6%. The FY2024 Fujian Laojiu acquisition (HK$51.6M) only masked organic decline: excluding wines, FY2024 revenue was HK$335.0M, down 12.7%. FY2025's 22.3% drop was broad-based. North American toy demand fell by HK$48.8M and Chinese herbs by HK$40.9M.
Profitability. Gross margin peaked at 43.2% in FY2023 on a richer herbs mix and has normalised to about 36%. The structural problem is overhead. Administrative expenses of HK$86.3M in FY2025 equal 28.7% of revenue, against 18.7% in FY2022, and staff costs in admin rose to HK$45.0M from HK$37.7M. Operating income turned negative in FY2025 for the first time since FY2021.
Below the line. Every year carries large associate losses (HK$46.4M in FY2025), finance costs (HK$31.8M) and recurring losses from issuing shares to creditors at below-market prices (HK$15.6M in FY2025, HK$17.2M in FY2024).
Balance sheet. Headline net debt has fallen from HK$270.6M (FY2022) to HK$100.7M (FY2025). This came from equity issuance and write-offs, not cash generation. The quality of liquidity has worsened: 97% of borrowings are current, a secured loan is in default, and net current liabilities persisted into mid-2026.
Working capital. Inventory days rose to 193 in FY2025, partly reflecting wine/F&B stock and slower toy turnover. Payables days stretched to 94, consistent with liquidity pressure.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Revenue-generating? |
|---|---|---|
Exploration | Minority interest in exploration rights of Bayanhushuo Coal Field and Guerbanhada Coal Mine, Inner Mongolia (about 500.05Mt JORC resources); held at FVTOCI and fully written down in FY2020 | No |
Toys and gifts items | Manufacturing and trading of toys and gifts | Yes |
Fruit plantation | Associates: Multijoy Group (40%; 1,765.53 mu forest land, Nanfeng County, Jiangxi) and USO Management & Holding (Samoa; resort/villa/casino development) | No (share of results) |
Leisure | Associates in PRC outbound tourism, tea (Fujian Yuguo) and wine (Anhui Fu Lao, 20%) | No (share of results) |
Culture | Trading of ceramic items | No revenue in FY2022–FY2025 |
Chinese herbs | Hubei Jincaotang (51%): development, processing, manufacturing of Chinese herbs | Yes |
Wines, food and beverage products | Fujian Laojiu (60%) wine trading; Heilongjiang Yingli F&B commission trading (Oct 2025 to H1 2026) | Yes |
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Toys and gifts items | 293.0 | 262.4 | 239.7 | 195.4 |
Chinese herbs | 127.9 | 121.5 | 95.3 | 54.4 |
Wines, food and beverage | 0 | 0 | 51.6 | 50.8 |
Total revenue | 420.9 | 383.9 | 386.7 | 300.6 |
Segment profit/(loss) (HKD Mn)
| Segment profit/(loss) (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Toys and gifts items | 21.2 | 5.5 | -12.4 | -20.6 |
Chinese herbs | 36.8 | 50.2 | 40.4 | 18.4 |
Wines, food and beverage | 0 | 0 | -0.7 | 1.2 |
Fruit plantation | -16.4 | -31.8 | -33.9 | -40.0 |
Leisure | -18.2 | -45.4 | -3.1 | -6.4 |
Culture | 0 | 0.6 | 0 | 0 |
Exploration | -0.05 | -0.01 | 0 | 0 |
Total segment result | 23.3 | -20.9 | -9.7 | -47.4 |
Segment margin (%)
| Segment margin (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Toys and gifts items | 7.2 | 2.1 | -5.2 | -10.6 |
Chinese herbs | 28.8 | 41.3 | 42.4 | 33.8 |
Wines, food and beverage | 0 | 0 | -1.4 | 2.4 |
Segment revenue growth (%)
| Segment revenue growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Toys and gifts items | -10.5 | -8.6 | -18.5 |
Chinese herbs | -4.9 | -21.6 | -42.9 |
Wines, food and beverage | 0 | 0 | -1.5 |
Group | -8.8 | 0.7 | -22.3 |
% of group revenue (%)
| % of group revenue (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Toys and gifts items | 69.6 | 68.3 | 62.0 |
Chinese herbs | 30.4 | 31.7 | 24.6 |
Wines, food and beverage | 0 | 0 | 13.4 |
Toys gross margin (%)
| Toys gross margin (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Toys and gifts GPM | 35.5 | 37.1 | 37.7 | 35.9 |
Segment Overview (Half-Yearly)
| Segment | H1 2026 revenue (HKD Mn) | Segment result |
|---|---|---|
Toys and gifts | 75.5 | Loss of about HK$8.68M |
Chinese herbs | 31.0 | — |
Wines, food and beverage | 62.7 (reported as down about 20.2%) | Profit of about HK$0.9M |
Total | 169.1 (vs 203.3 in H1 2025, -16.8%) | Attributable loss about HK$18.0M |
“—” = not publicly disclosed.
Income Statement
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 323.7 | 420.9 | 383.9 | 386.7 | 300.6 |
Cost of sales | 231.8 | 263.9 | 218.1 | 245.0 | 192.4 |
Gross profit | 91.9 | 157.0 | 165.8 | 141.7 | 108.2 |
Selling and distribution costs | 0 | 47.1 | 37.3 | 36.2 | 34.8 |
Administrative expenses | 0 | 78.8 | 86.4 | 83.0 | 86.3 |
Operating income (GP less S&D less admin; derived) | -19.3 | 31.1 | 42.1 | 22.5 | -12.9 |
Depreciation and amortisation | 29.1 | 34.5 | 15.7 | 17.5 | 16.6 |
EBITDA (derived) | -57.6 | 65.6 | 57.8 | 40.0 | 3.7 |
Finance costs | 0 | 46.8 | 27.1 | 28.9 | 31.8 |
Share of results of associates | 0 | -19.5 | -22.0 | -36.8 | -46.4 |
Pre-tax income | -219.5 | -29.4 | 69.1 | -65.8 | -103.4 |
Income tax expense | 0 | 9.1 | 3.4 | 7.0 | 7.8 |
Profit/(loss) for the year | 0 | -38.5 | 65.7 | -72.8 | -111.2 |
Net income attributable to owners | -226.8 | -59.5 | 37.2 | -84.6 | -121.7 |
Non-controlling interests | 0 | 21.0 | 28.5 | 11.8 | 10.6 |
Balance Sheet
| Item (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Cancellation of time-barred promissory notes (gain) | 0 | 92.0 | 0 | 0 |
Gain/(loss) on extinguishment of liabilities by share issue | 0 | 28.4 | -17.2 | -15.6 |
Impairment of investment in associates | 0 | -34.3 | 0 | 0 |
ECL impairment (net) | -0.4 | -27.5 | -9.0 | 1.9 |
Fair value gain on contingent consideration | 12.3 | 5.0 | 0 | 0 |
Per share
| Per share | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Basic/diluted EPS as reported (HK cents) | -58.72 | 19.53 | -24.83 | -14.17 |
EPS adjusted for Jan-2024 2:1 consolidation (HK cents; derived) | -117.44 | 39.06 | -24.83 | -14.17 |
Dividends per share (HK cents) | 0 | 0 | 0 | 0 |
Weighted avg shares (M, as reported) | 101.4 | 190.6 | 340.9 | 859.4 |
Margin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 28.4 | 37.3 | 43.2 | 36.6 | 36.0 |
Operating margin | -6.0 | 7.4 | 11.0 | 5.8 | -4.3 |
EBITDA margin | -17.8 | 15.6 | 15.1 | 10.3 | 1.2 |
Net margin (attributable) | -70.1 | -14.1 | 9.7 | -21.9 | -40.5 |
Balance Sheet and Margin Analysis (%)
| Metric (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets | 879.9 | 770.3 | 796.6 | 769.7 |
Property, plant and equipment | 93.9 | 107.8 | 99.7 | 105.7 |
Investments in associates | 310.3 | 247.0 | 204.9 | 172.0 |
Goodwill | 54.8 | 50.9 | 50.2 | 52.8 |
Other intangible assets | 8.8 | 5.8 | 5.9 | 5.8 |
Goodwill and intangibles | 63.6 | 56.7 | 56.1 | 58.6 |
Inventories | 74.3 | 87.9 | 97.6 | 101.6 |
Trade and bills receivables | 57.3 | 57.2 | 57.4 | 41.6 |
Cash and equivalents | 99.1 | 111.9 | 135.9 | 156.2 |
Borrowings — current | 101.8 | 134.2 | 143.1 | 199.6 |
Borrowings — non-current | 7.9 | 7.6 | 0 | 3.5 |
Convertible bonds (current plus non-current) | 91.2 | 130.6 | 98.0 | 46.8 |
Promissory notes | 164.8 | 0 | 0 | 0 |
Lease liabilities | 3.9 | 2.6 | 6.2 | 7.1 |
Total debt incl. CBs, notes, leases (derived) | 369.6 | 275.0 | 247.3 | 256.9 |
Net debt (derived) | 270.6 | 163.1 | 111.4 | 100.7 |
Total liabilities | 594.9 | 430.3 | 413.0 | 433.4 |
Equity attributable to owners | 185.7 | 214.2 | 249.2 | 229.9 |
Non-controlling interests | 99.3 | 125.8 | 134.5 | 106.4 |
Total equity | 285.0 | 340.0 | 383.6 | 336.3 |
Net current assets/(liabilities) | -80.2 | 38.1 | -26.4 | -26.6 |
Company gearing ratio (%) | 166.6 | 89.1 | 68.0 | 72.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash-flow proxy (HKD Mn)
| Cash-flow proxy (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Additions to segment non-current assets (capex proxy) | 1.4 | 45.0 | 17.0 | 16.6 |
Dividends paid | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 |
Net change in cash balance (derived) | 0 | 12.8 | 24.0 | 20.3 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (attributable, avg owners' equity; FY2022 on ending equity) (%) | -32.0 | 18.6 | -36.5 | -50.8 |
ROA (loss for year / avg total assets; FY2022 on ending) (%) | -4.4 | 8.0 | -9.3 | -14.2 |
ROIC | 0 | 0 | 0 | 0 |
Current ratio (x) | 0.83 | 1.14 | 0.93 | 0.94 |
Debt/equity (total debt / total equity) (x) | 1.30 | 0.81 | 0.64 | 0.76 |
Net debt/EBITDA (x) | 4.1 | 2.8 | 2.8 | 27.2 |
Interest coverage (operating income / finance costs) (x) | 0.66 | 1.55 | 0.78 | -0.41 |
Asset turnover (x) | 0.48 | 0.47 | 0.49 | 0.38 |
DSO (days) | 49.7 | 54.4 | 54.2 | 50.5 |
DIO (days) | 102.8 | 147.1 | 145.4 | 192.7 |
DPO (days) | 20.8 | 37.0 | 40.8 | 93.7 |
Cash conversion cycle (days) | 131.7 | 164.5 | 158.8 | 149.5 |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
North America (USA and Canada) | 291.7 | 261.8 | 238.9 | 190.0 |
PRC (including Hong Kong) | 128.8 | 122.1 | 147.7 | 105.8 |
Europe (FY2025: UK; FY2022: EU incl. UK) | 0.2 | 0 | 0 | 4.6 |
Others (Asia, South America, Mexico) | 0.2 | 0 | 0.1 | 0.2 |
Total | 420.9 | 383.9 | 386.7 | 300.6 |
Region share of revenue (%)
| Region share of revenue (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
North America | 69.3 | 68.2 | 61.8 | 63.2 |
PRC (incl. HK) | 30.6 | 31.8 | 38.2 | 35.2 |
Europe | 0.1 | 0 | 0 | 1.5 |
Region growth (%)
| Region growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
North America | -10.3 | -8.7 | -20.5 |
PRC (incl. HK) | -5.2 | 21.0 | -28.4 |
Implied Mapping FY2025 Details
| Implied mapping FY2025 (HKD Mn) | North America | PRC (incl. HK) | Europe/Other |
|---|---|---|---|
Toys and gifts (195.4) | 190.0 | about 0.6 (residual) | 4.8 |
Chinese herbs (54.4) | 0 | 54.4 | 0 |
Wines, F&B (50.8) | 0 | 50.8 | 0 |
Customers over 10% of revenue (HKD Mn)
| Customers over 10% of revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Customer A (toys) | 119.6 | 98.8 | 123.2 | 79.6 |
Customer B (toys in FY2022–23; herbs in FY2024) | 81.5 | 76.4 | 57.0 | 0 |
Customer C (herbs in FY2023; F&B in FY2024–25) | 0 | 52.5 | 51.5 | 37.0 |
Customer D (toys, FY2024) | 0 | 0 | 50.7 | 0 |
Share of revenue from >10% customers (%) | 48 | 59 | 73 | 38.8 |
Share Price & Returns
| Reference point | Approx. price / indicator |
|---|---|
Around Mar 2025 | About HK$1.0 (market cap about HK$813M on about 789M shares; insider purchase at avg HK$0.99) |
Jun 2025 | Down about 66% YTD |
21 Jul 2025 | HK$0.53 market price at subscription completion |
Mid-2026 | About HK$0.084–0.10 |
1-year performance (Oct 2025 to Oct 2026) | Not precisely verified; estimated decline of 70–80% |
3-year / 5-year | Not meaningful after three consolidations (2022, 2023, 2024). Aggregator shows annualised return since listing of about -22.8% |
Valuation Multiples
| Multiple | AOM | Peers |
|---|---|---|
P/E (trailing) | Negative (aggregator about -0.9x) | Hang Seng toys sub-industry about 17–19x (aggregator) |
P/B (on FY2025 owners' equity of HK$229.9M) | About 0.5x | Sub-industry about 4.6–5.1x (aggregator) |
EV/Sales (EV = market cap about 115 plus net debt 100.7 plus NCI 106.4; derived) | About 1.07x (incl. NCI); about 0.72x (excl. NCI) | n/v |
EV/EBITDA (FY2025 EBITDA HK$3.7M) | Over 50x (not meaningful) | n/v |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No sell-side coverage identified |
Dividend history | No dividends FY2022 to H1 2026; no stated dividend policy |
Buyback authorisations | Standard AGM general mandate only; no repurchases in FY2024 or FY2025 |
Debt Maturity Profile
| Maturity | Amount |
|---|---|
Due within 1 year (borrowings) | 199.6 |
Due after 1 year (borrowings) | 3.5 |
Convertible bonds (current) | 46.8 |
Lease liabilities (current / non-current) | 2.4 / 4.6 |
Issued shares (M)
| Issued shares (M) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Shares in issue at year end | 921.5 | 193.5 | 789.3 | 947.1 |
Share Price & Returns by Date
| Date | Instrument | Size | Price | Use |
|---|---|---|---|---|
Aug 2022 | Rights issue | 691.1M shares; HK$139.4M net | HK$0.205 | Debt settlement |
Jun 2023 | Loan capitalisation | 9.21M shares | HK$0.298 market | HK$31.1M debt |
Feb 2024 | CB placing | HK$45M | Conversion HK$0.15 | Capital base / business |
May 2024 | Loan capitalisation | 19.35M shares | HK$0.147 | HK$19.2M debt |
Sep 2024 | Placing | 470M shares; HK$51.3M net | HK$0.111 | Repay Hubei CB |
Oct 2024 | Loan capitalisation | 53.2M shares | Market HK$0.78 | HK$7.98M debt |
Jul 2025 | Subscription (set-off) | 157.8M shares; HK$68M | HK$0.4309 | Retire Second/Third Hubei CBs |
Jul 2026 | Specific-mandate share issue | About 236M shares (derived from share-count change) | — | Hubei CB loan capitalisation |
Jun 2026 (pending) | Consideration CB | HK$100M | Conversion HK$0.16 | Fujian Laojiu Sales 51% |
Analyst Conclusions
Management guidance and consensus
Management provides no quantitative guidance. The stated outlook is to keep reviewing operations and exploring investments that diversify income, and to improve the financial position through three steps: settling or extending the defaulted loans, relying on the shareholder's repayment deferral to Mar 2027, and raising capital through a rights issue, open offer, placing or CB. There is no consensus estimate.
Bull case
-
Herbs recovery. If plantation bases reach maturity and herb volumes recover toward FY2023 levels (HK$121.5M revenue, HK$50.2M segment profit), the group could return to segment-level profitability.
-
Wine distribution consolidation. The Fujian Laojiu Sales acquisition could combine brand, distribution and pricing power around Gushan huangjiu. Combined with stew-pot franchising, it might build a coherent PRC consumer business that already broke even in FY2025 (segment profit HK$1.2M).
-
Deep discount to book. At about 0.5x P/B against owners' equity of HK$229.9M, with HK$156.2M of year-end cash, successful restructuring of the defaulted debt could re-rate the shares. This depends on the associate carrying values (HK$172.0M) holding up.
Bear case
-
Solvency. A loan default, net current liabilities, an auditor's going-concern flag and borrowings rising to about HK$235M by Jun 2026, with negative operating income, point to continued reliance on dilutive rescue financing.
-
Core erosion. Toys revenue has fallen three years running (down 33% from FY2022) and has turned loss-making. It depends on a few US customers exposed to tariffs, and H1 2026 toys revenue was only HK$75.5M.
-
Value leakage. Share issues to creditors below market (losses of HK$17.2M in FY2024 and HK$15.6M in FY2025), dilutive acquisitions (up to 625M new shares) and associate write-downs consistently transfer value away from minority shareholders.
Key catalysts and monitorables (next 12 months)
-
Outcome of negotiations on the defaulted HK$63.9M secured loan.
-
Any rights issue, open offer or placing: size, discount, and underwriter or controlling-shareholder support.
-
Completion and circular details of the Fujian Laojiu Sales 51% deal, including target financials and valuation support for HK$100M.
-
Capital commitment to and economics of the Hainan Lianshang / Yuanmingtang JV.
-
FY2026 annual results (due by end-Mar 2027) and the auditor's opinion.
-
US tariff developments affecting China-made toys, and the trend in North American orders.
-
Herbs revenue trajectory and the plantation-base ramp.
-
USO Samoa construction start (targeted Oct 2026).
-
Anhui Fu Lao enforcement ruling.
-
Board stability under the new Chairman, Fan Xuefei.
-
The 31 Mar 2027 expiry of the shareholder's repayment deferral (HK$37.5M).
Analyst verdict
AOM International is a distressed micro-cap holding company, not an operating growth story. Over FY2022–FY2025 it lost money in three of four years. Its single profitable year (FY2023) came entirely from writing off time-barred promissory notes and gains on loan capitalisation. Its genuine operating assets are a shrinking toy OEM with healthy gross margins but a heavy overhead load, a once-lucrative TCM herbs subsidiary whose revenue fell 43% in FY2025, and a sub-scale Fujian wine trading platform. Beneath these sit associates in Jiangxi forest land, Samoan resort land, tea and Anhui huangjiu. Over four years these have absorbed more than HK$125M of share-of-losses and impairments, and their HK$172M carrying value remains the largest single asset line.
The balance sheet is the binding constraint. The group ended FY2025 with net current liabilities, HK$101.7M of defaulted secured principal and interest, and an unmodified audit opinion carrying a going-concern material uncertainty, which the H1 2026 interim repeated. Management's answer has been the same for years: issue equity to creditors at a discount, consolidate shares, and announce new ventures. The ventures now span stew-pot restaurants, premium "cultural export" huangjiu, cooking-wine distribution paid for with a HK$100M CB worth up to half the existing share capital, and a digital-economy and Samoa-listing services platform. None has a disclosed earnings track record, and several earlier initiatives were reversed within months: the Beijing HQ purchase and the Heilongjiang Yingli acquisition.
The shares trade at roughly half of book value, but that discount reflects high governance risk, asset-quality doubts and ongoing dilution. A credible re-rating would require three things: a negotiated resolution of the loan default, an orderly and preferably pre-emptive capital raise, and a demonstrated turnaround in herbs or wine profitability. Until then, the evidence supports a high-risk, avoid/speculative-only stance.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background (as disclosed) | Status (Oct 2026) |
|---|---|---|---|---|
Fan Xuefei (范雪飛) | Chairman, Executive Director | — | — | Chairman per 13 Aug 2026 notice |
Li Lizhong (李立中) | Executive Director; Co-Chairman | 4 Oct 2024 | Age 49 (per biography); chairman of Lizhan Group; described as a blockchain/digital-currency scientist with over 100 patents (70+ blockchain); former senior role at Ant Financial; numerous academic and association titles | Serving; bought 14.2M shares at avg HK$0.99 (early 2025, per news feed) |
Liu Mingqing (劉明卿) | Executive Director | 27 Mar 2020 | — | Serving |
Yang Bincheng (楊斌成) | Executive Director | — | — | Serving |
Tang Sing Hing, Kenny (鄧聲興) | Non-executive Director | — | — | Serving |
Chak Ching Long (翟正龍) | INED; Audit Committee | — | — | Serving |
Wang Xiao Ning (王曉寧) | INED; Audit Committee | — | — | Serving |
Chen Yuxin (陳雨鑫) | INED; Audit Committee | 13 May 2020 | — | Serving |
Yang Ling (楊鈴) | Former Chairman, ED | ED 5 Apr 2024; Chairman 4 Oct 2024 | Age 40; Vice President of Fujian Laojiu Investment Group since 2021 | No longer on board by 13 Aug 2026 (an executive director resignation was announced 15 Jul 2026; identity not confirmed from primary text) |
Sun Weiwei (孫維維) | Former ED | 5 Sep 2023 | — | Resigned 24 Jun 2025 (personal commitments) |
Zhang Qijun (張啟軍) | Former Chairman | — | — | Chairman as of Mar 2024; succeeded by Yang Ling Oct 2024 |
Wei Yu (魏鈺) | Former INED | 19 Jun 2023 | — | Replaced on Audit Committee by Chak Ching Long |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Notes |
|---|---|---|
Yang Zhu (vendor, Fujian Laojiu Sales) | Up to 625M conversion shares if CB converted | About 34.6% of the enlarged share capital on announcement basis |
Feb 2024 CB placees | About 60.37% (as reported by news feed after conversion) | No fewer than six placees |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing | Approx. scale | Relative positioning vs AOM |
|---|---|---|---|---|
Toys (OEM/licensed) | Dream International | HKEX 1126 | Multi-billion HK$ revenue | Far larger OEM plush/plastic toy maker for global brands |
Toys | Kader Holdings | HKEX 0180 | Several hundred million HK$ | Comparable heritage HK toy OEM |
Toys | Playmates Holdings / Playmates Toys | HKEX 0635 / 0869 | Hundreds of millions to billions HK$ | Own-brand/licensed toys for the US market |
Toys | Herald Holdings | HKEX 0114 | Hundreds of millions HK$ | Diversified HK toy/houseware maker |
Toys | Pop Mart International | HKEX 9992 | Tens of billions RMB | Designer-toy leader; different model, competes for licensed-IP shelf space |
TCM herbs | China Traditional Chinese Medicine Holdings | HKEX 0570 | Billions RMB | Leading TCM granule/decoction player |
TCM herbs | Beijing Tong Ren Tang | SSE 600085 / HKEX 1666 | Billions RMB | Premier TCM brand |
TCM herbs | China Resources Sanjiu | SZSE 000999 | Billions RMB | Scale TCM pharmaceutical |
Huangjiu | Zhejiang Guyue Longshan Shaoxing Wine | SSE 600059 | About RMB2bn | Category leader (Shaoxing) |
Huangjiu | Kuaijishan Shaoxing Wine | SSE 601579 | About RMB1–2bn | Major Shaoxing brand |
Huangjiu | Shanghai Jinfeng Wine | SSE 600616 | Hundreds of millions RMB | Shanghai-style huangjiu |
Peer Comparison FY2025
| Metric | AOM (FY2025, verified) | Dream Intl | Kader | Guyue Longshan |
|---|---|---|---|---|
Revenue | HK$300.6M | Multi-billion HK$ | Several hundred million HK$ | About RMB2bn |
Revenue growth | -22.3% | n/v | n/v | n/v |
Gross margin | 36.0% | n/v | n/v | n/v |
Operating margin | -4.3% (derived) | n/v | n/v | n/v |
R&D intensity | 2.2% | n/v | n/v | n/v |
Recent Developments
--



